On 19 November 2014, orphan designation (EU/3/14/1355) was granted by the European Commission to Clinipace GmbH, Germany, for selinexor for the treatment of plasma cell myeloma.
The sponsorship was transferred to Karyopharm Europe GmbH, Germany, in August 2015.
Please note that this product (marketed as product name Nexpovio) was withdrawn from the Union Register of orphan medicinal products in February 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
Treatment of plasma cell myeloma
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.